{"id":63017,"date":"2025-12-22T08:56:40","date_gmt":"2025-12-21T23:56:40","guid":{"rendered":"https:\/\/www.marketresearch.co.jp\/insights\/anti-vegf-therapeutics-market-straits\/"},"modified":"2026-09-18T04:15:42","modified_gmt":"2026-09-17T19:15:42","slug":"anti-vegf-therapeutics-market-straits","status":"publish","type":"post","link":"https:\/\/www.marketresearch.co.jp\/insights\/anti-vegf-therapeutics-market-straits\/","title":{"rendered":"Anti-VEGF\u6cbb\u7642\u85ac \u5e02\u5834\u898f\u6a21\u3068\u5c55\u671b\u30012025-2033\u5e74"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.marketresearch.co.jp\/insights\/wp-content\/uploads\/2025\/12\/1708438528-anti-vegf-therapeutics-market.jpg\" alt=\"Market Image 1\" style=\"max-width:100%; height:auto; margin-bottom: 20px;\" \/><br \/><img decoding=\"async\" src=\"https:\/\/www.marketresearch.co.jp\/insights\/wp-content\/uploads\/2025\/12\/market-share.webp-4869.jpg\" alt=\"Market Image 2\" style=\"max-width:100%; height:auto; margin-bottom: 20px;\" \/><\/p>\n<h2>Report Coverage &#038; Structure<\/h2>\n<ul>\n<li>Segmentation<\/li>\n<li>\u30bb\u30b0\u30e1\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3<\/li>\n<li>Research Methodology<\/li>\n<li>\u8abf\u67fb\u65b9\u6cd5\u8ad6<\/li>\n<li>Get Free Sample<\/li>\n<li>\u7121\u6599\u30b5\u30f3\u30d7\u30eb\u3092\u5165\u624b<\/li>\n<li>Table Of Content<\/li>\n<ul>\n<li>Executive Summary<\/li>\n<li>\u30a8\u30b0\u30bc\u30af\u30c6\u30a3\u30d6\u30b5\u30de\u30ea\u30fc<\/li>\n<li>Research Scope &#038; Segmentation<\/li>\n<li>\u8abf\u67fb\u7bc4\u56f2\u3068\u30bb\u30b0\u30e1\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3<\/li>\n<li>Research Objectives<\/li>\n<li>\u8abf\u67fb\u76ee\u7684<\/li>\n<li>Limitations &#038; Assumptions<\/li>\n<li>\u5236\u9650\u4e8b\u9805\u3068\u4eee\u5b9a<\/li>\n<li>Market Scope &#038; Segmentation<\/li>\n<li>\u5e02\u5834\u7bc4\u56f2\u3068\u30bb\u30b0\u30e1\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3<\/li>\n<li>Currency &#038; Pricing Considered<\/li>\n<li>\u8003\u616e\u3055\u308c\u308b\u901a\u8ca8\u3068\u4fa1\u683c\u8a2d\u5b9a<\/li>\n<li>Market Opportunity Assessment<\/li>\n<li>\u5e02\u5834\u6a5f\u4f1a\u8a55\u4fa1<\/li>\n<ul>\n<li>Emerging Regions \/ Countries<\/li>\n<li>\u65b0\u8208\u5730\u57df\/\u56fd<\/li>\n<li>Emerging Companies<\/li>\n<li>\u65b0\u8208\u4f01\u696d<\/li>\n<li>Emerging Applications \/ End Use<\/li>\n<li>\u65b0\u8208\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\/\u6700\u7d42\u7528\u9014<\/li>\n<\/ul>\n<li>Market Trends<\/li>\n<li>\u5e02\u5834\u52d5\u5411<\/li>\n<ul>\n<li>Drivers<\/li>\n<li>\u63a8\u9032\u8981\u56e0<\/li>\n<li>Market Warning Factors<\/li>\n<li>\u5e02\u5834\u8b66\u544a\u8981\u56e0<\/li>\n<li>Latest Macro Economic Indicators<\/li>\n<li>\u6700\u65b0\u306e\u30de\u30af\u30ed\u7d4c\u6e08\u6307\u6a19<\/li>\n<li>Geopolitical Impact<\/li>\n<li>\u5730\u653f\u5b66\u7684\u5f71\u97ff<\/li>\n<li>Technology Factors<\/li>\n<li>\u6280\u8853\u7684\u8981\u56e0<\/li>\n<\/ul>\n<li>Market Assessment<\/li>\n<li>\u5e02\u5834\u8a55\u4fa1<\/li>\n<ul>\n<li>Porters Five Forces Analysis<\/li>\n<li>\u30dd\u30fc\u30bf\u30fc\u306e\u30d5\u30a1\u30a4\u30d6\u30d5\u30a9\u30fc\u30b9\u5206\u6790<\/li>\n<li>Value Chain Analysis<\/li>\n<li>\u30d0\u30ea\u30e5\u30fc\u30c1\u30a7\u30fc\u30f3\u5206\u6790<\/li>\n<\/ul>\n<li>Regulatory Framework<\/li>\n<li>\u898f\u5236\u306e\u67a0\u7d44\u307f<\/li>\n<ul>\n<li>North America<\/li>\n<li>\u5317\u7c73<\/li>\n<li>Europe<\/li>\n<li>\u6b27\u5dde<\/li>\n<li>APAC<\/li>\n<li>APAC<\/li>\n<li>Middle East and Africa<\/li>\n<li>\u4e2d\u6771\u304a\u3088\u3073\u30a2\u30d5\u30ea\u30ab<\/li>\n<li>LATAM<\/li>\n<li>LATAM<\/li>\n<\/ul>\n<li>ESG Trends<\/li>\n<li>ESG\u30c8\u30ec\u30f3\u30c9<\/li>\n<li>Global Anti-VEGF Therapeutics Market Size Analysis<\/li>\n<li>\u4e16\u754c\u306eAnti-VEGF\u6cbb\u7642\u85ac\u5e02\u5834\u898f\u6a21\u5206\u6790<\/li>\n<ul>\n<li>Global Anti-VEGF Therapeutics Market Introduction<\/li>\n<li>\u4e16\u754c\u306eAnti-VEGF\u6cbb\u7642\u85ac\u5e02\u5834\u306e\u6982\u8981<\/li>\n<ul>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<\/ul>\n<\/ul>\n<li>North America Market Analysis<\/li>\n<li>\u5317\u7c73\u5e02\u5834\u5206\u6790<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>U.S.<\/li>\n<li>\u7c73\u56fd<\/li>\n<ul>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<\/ul>\n<li>Canada<\/li>\n<li>\u30ab\u30ca\u30c0<\/li>\n<\/ul>\n<li>Europe Market Analysis<\/li>\n<li>\u6b27\u5dde\u5e02\u5834\u5206\u6790<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>U.K.<\/li>\n<li>\u82f1\u56fd<\/li>\n<ul>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<\/ul>\n<li>Germany<\/li>\n<li>\u30c9\u30a4\u30c4<\/li>\n<li>France<\/li>\n<li>\u30d5\u30e9\u30f3\u30b9<\/li>\n<li>Spain<\/li>\n<li>\u30b9\u30da\u30a4\u30f3<\/li>\n<li>Italy<\/li>\n<li>\u30a4\u30bf\u30ea\u30a2<\/li>\n<li>Russia<\/li>\n<li>\u30ed\u30b7\u30a2<\/li>\n<li>Nordic<\/li>\n<li>\u5317\u6b27<\/li>\n<li>Benelux<\/li>\n<li>\u30d9\u30cd\u30eb\u30af\u30b9<\/li>\n<li>Rest of Europe<\/li>\n<li>\u305d\u306e\u4ed6\u306e\u6b27\u5dde\u5730\u57df<\/li>\n<\/ul>\n<li>APAC Market Analysis<\/li>\n<li>APAC\u5e02\u5834\u5206\u6790<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>China<\/li>\n<li>\u4e2d\u56fd<\/li>\n<ul>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<\/ul>\n<li>Korea<\/li>\n<li>\u97d3\u56fd<\/li>\n<li>Japan<\/li>\n<li>\u65e5\u672c<\/li>\n<li>India<\/li>\n<li>\u30a4\u30f3\u30c9<\/li>\n<li>Australia<\/li>\n<li>\u30aa\u30fc\u30b9\u30c8\u30e9\u30ea\u30a2<\/li>\n<li>Taiwan<\/li>\n<li>\u53f0\u6e7e<\/li>\n<li>South East Asia<\/li>\n<li>\u6771\u5357\u30a2\u30b8\u30a2<\/li>\n<li>Rest of Asia-Pacific<\/li>\n<li>\u305d\u306e\u4ed6\u306e\u30a2\u30b8\u30a2\u592a\u5e73\u6d0b\u5730\u57df<\/li>\n<\/ul>\n<li>Middle East and Africa Market Analysis<\/li>\n<li>\u4e2d\u6771\u304a\u3088\u3073\u30a2\u30d5\u30ea\u30ab\u5e02\u5834\u5206\u6790<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>UAE<\/li>\n<li>\u30a2\u30e9\u30d6\u9996\u9577\u56fd\u9023\u90a6<\/li>\n<ul>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<\/ul>\n<li>Turkey<\/li>\n<li>\u30c8\u30eb\u30b3<\/li>\n<li>Saudi Arabia<\/li>\n<li>\u30b5\u30a6\u30b8\u30a2\u30e9\u30d3\u30a2<\/li>\n<li>South Africa<\/li>\n<li>\u5357\u30a2\u30d5\u30ea\u30ab<\/li>\n<li>Egypt<\/li>\n<li>\u30a8\u30b8\u30d7\u30c8<\/li>\n<li>Nigeria<\/li>\n<li>\u30ca\u30a4\u30b8\u30a7\u30ea\u30a2<\/li>\n<li>Rest of MEA<\/li>\n<li>\u305d\u306e\u4ed6\u306e\u4e2d\u6771\u304a\u3088\u3073\u30a2\u30d5\u30ea\u30ab\u5730\u57df<\/li>\n<\/ul>\n<li>LATAM Market Analysis<\/li>\n<li>LATAM\u5e02\u5834\u5206\u6790<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>Brazil<\/li>\n<li>\u30d6\u30e9\u30b8\u30eb<\/li>\n<ul>\n<li>By Products<\/li>\n<li>\u88fd\u54c1\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Products By Value<\/li>\n<li>\u88fd\u54c1\u5225\u4fa1\u5024<\/li>\n<li>Eylea<\/li>\n<li>\u30a2\u30a4\u30ea\u30fc\u30a2<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Lucentis<\/li>\n<li>\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Beovu<\/li>\n<li>\u30d9\u30aa\u30d3\u30e5<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<li>By Disease<\/li>\n<li>\u75be\u60a3\u5225<\/li>\n<ul>\n<li>Introduction<\/li>\n<li>\u6982\u8981<\/li>\n<li>Disease By Value<\/li>\n<li>\u75be\u60a3\u5225\u4fa1\u5024<\/li>\n<li>Macular Edema<\/li>\n<li>\u9ec4\u6591\u6d6e\u816b<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Diabetic Retinopathy<\/li>\n<li>\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Retinal Vein Occlusion<\/li>\n<li>\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<li>Age-related Macular Degeneration<\/li>\n<li>\u52a0\u9f62\u9ec4\u6591\u5909\u6027<\/li>\n<ul>\n<li>By Value<\/li>\n<li>\u4fa1\u5024\u5225<\/li>\n<\/ul>\n<\/ul>\n<\/ul>\n<li>Mexico<\/li>\n<li>\u30e1\u30ad\u30b7\u30b3<\/li>\n<li>Argentina<\/li>\n<li>\u30a2\u30eb\u30bc\u30f3\u30c1\u30f3<\/li>\n<li>Chile<\/li>\n<li>\u30c1\u30ea<\/li>\n<li>Colombia<\/li>\n<li>\u30b3\u30ed\u30f3\u30d3\u30a2<\/li>\n<li>Rest of LATAM<\/li>\n<li>\u305d\u306e\u4ed6\u306eLATAM\u5730\u57df<\/li>\n<\/ul>\n<li>Competitive Landscape<\/li>\n<li>\u7af6\u5408\u60c5\u52e2<\/li>\n<ul>\n<li>Anti-VEGF Therapeutics Market Share By Players<\/li>\n<li>Anti-VEGF\u6cbb\u7642\u85ac\u5e02\u5834\u306e\u30d7\u30ec\u30fc\u30e4\u30fc\u5225\u30b7\u30a7\u30a2<\/li>\n<li>M&#038;A Agreements &#038; Collaboration Analysis<\/li>\n<li>M&#038;A\u5951\u7d04\u304a\u3088\u3073\u63d0\u643a\u5206\u6790<\/li>\n<\/ul>\n<li>Market Players Assessment<\/li>\n<li>\u5e02\u5834\u30d7\u30ec\u30fc\u30e4\u30fc\u8a55\u4fa1<\/li>\n<ul>\n<li>Regeneron Pharmaceuticals, Inc.<\/li>\n<li>Regeneron Pharmaceuticals, Inc.<\/li>\n<ul>\n<li>Overview<\/li>\n<li>\u6982\u8981<\/li>\n<li>Business Information<\/li>\n<li>\u4e8b\u696d\u60c5\u5831<\/li>\n<li>Revenue<\/li>\n<li>\u53ce\u76ca<\/li>\n<li>ASP<\/li>\n<li>ASP<\/li>\n<li>SWOT Analysis<\/li>\n<li>SWOT\u5206\u6790<\/li>\n<li>Recent Developments<\/li>\n<li>\u6700\u8fd1\u306e\u52d5\u5411<\/li>\n<\/ul>\n<li>Bayer AG<\/li>\n<li>Bayer AG<\/li>\n<li>F. Hoffmann-La Roche Ltd<\/li>\n<li>F. Hoffmann-La Roche Ltd<\/li>\n<li>Biogen<\/li>\n<li>Biogen<\/li>\n<li>Pfizer, Inc.<\/li>\n<li>Pfizer, Inc.<\/li>\n<li>Coherus BioSciences<\/li>\n<li>Coherus BioSciences<\/li>\n<li>Amgen, Inc.<\/li>\n<li>Amgen, Inc.<\/li>\n<li>Bausch Health Companies, Inc.<\/li>\n<li>Bausch Health Companies, Inc.<\/li>\n<li>Viatris, Inc.<\/li>\n<li>Viatris, Inc.<\/li>\n<li>Novartis AG<\/li>\n<li>Novartis AG<\/li>\n<\/ul>\n<li>Research Methodology<\/li>\n<li>\u8abf\u67fb\u65b9\u6cd5\u8ad6<\/li>\n<ul>\n<li>Research Data<\/li>\n<li>\u8abf\u67fb\u30c7\u30fc\u30bf<\/li>\n<ul>\n<li>Secondary Data<\/li>\n<li>\u4e8c\u6b21\u30c7\u30fc\u30bf<\/li>\n<li>Major secondary sources<\/li>\n<li>\u4e3b\u8981\u306a\u4e8c\u6b21\u60c5\u5831\u6e90<\/li>\n<li>Key data from secondary sources<\/li>\n<li>\u4e8c\u6b21\u60c5\u5831\u6e90\u304b\u3089\u306e\u4e3b\u8981\u30c7\u30fc\u30bf<\/li>\n<\/ul>\n<li>Primary Data<\/li>\n<li>\u4e00\u6b21\u30c7\u30fc\u30bf<\/li>\n<ul>\n<li>Key data from primary sources<\/li>\n<li>\u4e00\u6b21\u60c5\u5831\u6e90\u304b\u3089\u306e\u4e3b\u8981\u30c7\u30fc\u30bf<\/li>\n<li>Breakdown of primaries<\/li>\n<li>\u4e00\u6b21\u60c5\u5831\u306e\u5185\u8a33<\/li>\n<\/ul>\n<li>Secondary And Primary Research<\/li>\n<li>\u4e8c\u6b21\u304a\u3088\u3073\u4e00\u6b21\u8abf\u67fb<\/li>\n<ul>\n<li>Key industry insights<\/li>\n<li>\u4e3b\u8981\u306a\u696d\u754c\u30a4\u30f3\u30b5\u30a4\u30c8<\/li>\n<\/ul>\n<li>Market Size Estimation<\/li>\n<li>\u5e02\u5834\u898f\u6a21\u63a8\u5b9a<\/li>\n<ul>\n<li>Bottom-Up Approach<\/li>\n<li>\u30dc\u30c8\u30e0\u30a2\u30c3\u30d7\u30a2\u30d7\u30ed\u30fc\u30c1<\/li>\n<li>Top-Down Approach<\/li>\n<li>\u30c8\u30c3\u30d7\u30c0\u30a6\u30f3\u30a2\u30d7\u30ed\u30fc\u30c1<\/li>\n<li>Market Projection<\/li>\n<li>\u5e02\u5834\u4e88\u6e2c<\/li>\n<\/ul>\n<li>Research Assumptions<\/li>\n<li>\u8abf\u67fb\u306e\u4eee\u5b9a<\/li>\n<ul>\n<li>Assumptions<\/li>\n<li>\u4eee\u5b9a<\/li>\n<\/ul>\n<li>Limitations<\/li>\n<li>\u5236\u9650\u4e8b\u9805<\/li>\n<li>Risk Assessment<\/li>\n<li>\u30ea\u30b9\u30af\u8a55\u4fa1<\/li>\n<\/ul>\n<li>Appendix<\/li>\n<li>\u4ed8\u9332<\/li>\n<ul>\n<li>Discussion Guide<\/li>\n<li>\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3\u30ac\u30a4\u30c9<\/li>\n<li>Customization Options<\/li>\n<li>\u30ab\u30b9\u30bf\u30de\u30a4\u30ba\u30aa\u30d7\u30b7\u30e7\u30f3<\/li>\n<li>Related Reports<\/li>\n<li>\u95a2\u9023\u30ec\u30dd\u30fc\u30c8<\/li>\n<\/ul>\n<li>Disclaimer<\/li>\n<li>\u514d\u8cac\u4e8b\u9805<\/li>\n<\/ul>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>\u4e16\u754c\u306eAnti-VEGF\u6cbb\u7642\u85ac\u5e02\u5834\u306f\u30012024\u5e74\u306b124.5\u5104\u7c73\u30c9\u30eb\u306e\u898f\u6a21\u306b\u9054\u3057\u30012025\u5e74\u306b\u306f125.2\u5104\u7c73\u30c9\u30eb\u30012033\u5e74\u307e\u3067\u306b\u306f131.4\u5104\u7c73\u30c9\u30eb\u306b\u6210\u9577\u3059\u308b\u3068\u4e88\u6e2c\u3055\u308c\u3066\u304a\u308a\u3001\u4e88\u6e2c\u671f\u9593\uff082025\u5e74\uff5e2033\u5e74\uff09\u306b\u304a\u3051\u308b\u5e74\u5e73\u5747\u6210\u9577\u7387\uff08CAGR\uff09\u306f0.6%\u3068\u898b\u8fbc\u307e\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u5e02\u5834\u306e\u6210\u9577\u306f\u3001\u773c\u79d1\u75be\u60a3\u306e\u6709\u75c5\u7387\u5897\u52a0\u3001\u9ad8\u9f62\u8005\u4eba\u53e3\u306e\u62e1\u5927\u3001\u305d\u3057\u3066\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u306b\u5411\u3051\u305f\u7814\u7a76\u958b\u767a\u6295\u8cc7\u306e\u6d3b\u767a\u5316\u306b\u3088\u3063\u3066\u727d\u5f15\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>**1. \u5e02\u5834\u6982\u8981\u3068Anti-VEGF\u6cbb\u7642\u85ac\u306e\u91cd\u8981\u6027**<\/p>\n<p>\u8840\u7ba1\u5185\u76ae\u5897\u6b96\u56e0\u5b50\uff08VEGF\uff09\u306f\u3001\u4eba\u4f53\u304c\u81ea\u7136\u306b\u751f\u6210\u3059\u308b\u30b7\u30b0\u30ca\u30eb\u30bf\u30f3\u30d1\u30af\u8cea\u3067\u3042\u308a\u3001\u80da\u767a\u751f\u671f\u304b\u3089\u6210\u4eba\u671f\u306b\u81f3\u308b\u307e\u3067\u3001\u65b0\u3057\u3044\u8840\u7ba1\u306e\u5f62\u6210\uff08\u8840\u7ba1\u65b0\u751f\uff09\u3068\u65e2\u5b58\u8840\u7ba1\u306e\u7dad\u6301\u306b\u304a\u3044\u3066\u6975\u3081\u3066\u91cd\u8981\u306a\u5f79\u5272\u3092\u62c5\u3063\u3066\u3044\u307e\u3059\u3002\u3057\u304b\u3057\u3001\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7\u3001\u8840\u7ba1\u9589\u585e\u3001\u52a0\u9f62\u9ec4\u6591\u5909\u6027\u75c7\uff08AMD\uff09\u3068\u3044\u3063\u305f\u7279\u5b9a\u306e\u75c5\u614b\u4e0b\u3067\u306f\u3001VEGF\u306e\u904e\u5270\u306a\u767a\u73fe\u3084\u7570\u5e38\u306a\u6d3b\u6027\u5316\u304c\u3001\u5236\u5fa1\u4e0d\u80fd\u306a\u65b0\u751f\u8840\u7ba1\u306e\u5897\u6b96\u3092\u5f15\u304d\u8d77\u3053\u3057\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u7570\u5e38\u306a\u8840\u7ba1\u306f\u3001\u8106\u5f31\u3067\u900f\u904e\u6027\u304c\u9ad8\u304f\u3001\u51fa\u8840\u3084\u4f53\u6db2\u306e\u6f0f\u51fa\u3092\u4f34\u3044\u3001\u6700\u7d42\u7684\u306b\u306f\u7622\u75d5\u7d44\u7e54\u306e\u5f62\u6210\u3092\u4fc3\u3057\u3001\u4e0d\u53ef\u9006\u7684\u306a\u8996\u529b\u55aa\u5931\u3078\u3068\u7e4b\u304c\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>Anti-VEGF\u6cbb\u7642\u85ac\u306f\u3001\u3053\u306eVEGF\u306e\u6d3b\u52d5\u3092\u7279\u7570\u7684\u306b\u963b\u5bb3\u3059\u308b\u85ac\u5264\u3067\u3042\u308a\u3001\u7570\u5e38\u306a\u8840\u7ba1\u65b0\u751f\u3092\u6291\u5236\u3057\u3001\u8840\u7ba1\u304b\u3089\u306e\u6f0f\u51fa\u3092\u6e1b\u5c11\u3055\u305b\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u85ac\u5264\u30af\u30e9\u30b9\u306f\u3001\u4e3b\u306b\u773c\u79d1\u9818\u57df\u306b\u304a\u3044\u3066\u3001\u6ef2\u51fa\u578b\u52a0\u9f62\u9ec4\u6591\u5909\u6027\u75c7\uff08\u30a6\u30a7\u30c3\u30c8AMD\uff09\u3001\u7cd6\u5c3f\u75c5\u9ec4\u6591\u6d6e\u816b\uff08DME\uff09\u3001\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7\uff08RVO\uff09\u306b\u4f34\u3046\u9ec4\u6591\u6d6e\u816b\u3001\u304a\u3088\u3073\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7\uff08DR\uff09\u306a\u3069\u306e\u6cbb\u7642\u306b\u7528\u3044\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u4e00\u90e8\u306eAnti-VEGF\u85ac\u5264\u306f\u3001\u304c\u3093\u6cbb\u7642\u306b\u304a\u3044\u3066\u3082\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u3068\u3057\u3066\u5fdc\u7528\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u9069\u5207\u306a\u6761\u4ef6\u4e0b\u3067Anti-VEGF\u6cbb\u7642\u85ac\u304c\u4f7f\u7528\u3055\u308c\u308b\u3053\u3068\u3067\u3001\u5206\u5b50\u30ec\u30d9\u30eb\u3067VEGF\u306e\u6a5f\u80fd\u3092\u52b9\u679c\u7684\u306b\u30d6\u30ed\u30c3\u30af\u3057\u3001\u3053\u308c\u3089\u306e\u91cd\u7be4\u306a\u773c\u75be\u60a3\u306b\u3088\u308b\u7f79\u60a3\u7387\u3092\u5927\u5e45\u306b\u4f4e\u4e0b\u3055\u305b\u3001\u60a3\u8005\u306e\u8996\u529b\u7dad\u6301\u3068\u751f\u6d3b\u306e\u8cea\u306e\u5411\u4e0a\u306b\u8ca2\u732e\u3059\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u305d\u306e\u6cbb\u7642\u52b9\u679c\u306e\u9ad8\u3055\u304b\u3089\u3001Anti-VEGF\u6cbb\u7642\u85ac\u306f\u3001\u73fe\u4ee3\u306e\u773c\u79d1\u6cbb\u7642\u306b\u304a\u3044\u3066\u6b20\u304b\u305b\u306a\u3044\u57fa\u5e79\u85ac\u5264\u3068\u3057\u3066\u306e\u5730\u4f4d\u3092\u78ba\u7acb\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>**2. \u5e02\u5834\u306e\u4fc3\u9032\u8981\u56e0**<\/p>\n<p>Anti-VEGF\u6cbb\u7642\u85ac\u5e02\u5834\u306e\u6210\u9577\u3092\u63a8\u9032\u3059\u308b\u8981\u56e0\u306f\u591a\u5c90\u306b\u308f\u305f\u308a\u3001\u305d\u306e\u4e2d\u3067\u3082\u7279\u306b\u4ee5\u4e0b\u306e\u70b9\u304c\u6319\u3052\u3089\u308c\u307e\u3059\u3002<\/p>\n<p>*   **\u773c\u79d1\u75be\u60a3\u306e\u767a\u751f\u7387\u306e\u7d99\u7d9a\u7684\u306a\u5897\u52a0**:<br \/>\n    \u52a0\u9f62\u9ec4\u6591\u5909\u6027\u75c7\uff08AMD\uff09\u3001\u7cd6\u5c3f\u75c5\u9ec4\u6591\u6d6e\u816b\u3001\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7\u3001\u7cd6\u5c3f\u75c5\u7db2\u819c\u75c7\u3068\u3044\u3063\u305f\u4e3b\u8981\u306a\u773c\u79d1\u75be\u60a3\u306e\u767a\u751f\u7387\u304c\u4e16\u754c\u7684\u306b\u4e0a\u6607\u3057\u3066\u3044\u308b\u3053\u3068\u304c\u3001Anti-VEGF\u6cbb\u7642\u85ac\u306e\u9700\u8981\u3092\u5f37\u529b\u306b\u62bc\u3057\u4e0a\u3052\u3066\u3044\u307e\u3059\u3002\u7279\u306bAMD\u306f\u3001\u9ad8\u9f62\u8005\u306b\u591a\u304f\u898b\u3089\u308c\u308b\u9032\u884c\u6027\u306e\u773c\u75be\u60a3\u3067\u3042\u308a\u3001\u4e2d\u5fc3\u8996\u529b\u306b\u4e0d\u53ef\u9006\u7684\u306a\u969c\u5bb3\u3092\u3082\u305f\u3089\u3057\u307e\u3059\u3002\u4e16\u754c\u4fdd\u5065\u6a5f\u95a2\uff08WHO\uff09\u306e\u5831\u544a\u306b\u3088\u308c\u3070\u3001\u4e16\u754c\u4e2d\u3067\u7d041\u51049600\u4e07\u4eba\u304cAMD\u306b\u7f79\u60a3\u3057\u3066\u304a\u308a\u3001\u305d\u306e\u3046\u30611040\u4e07\u4eba\u4ee5\u4e0a\u304c\u4e2d\u7b49\u5ea6\u304b\u3089\u91cd\u5ea6\u306e\u8996\u899a\u969c\u5bb3\u3092\u62b1\u3048\u3066\u3044\u308b\u3068\u3055\u308c\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u75be\u60a3\u306f\u60a3\u8005\u306e\u751f\u6d3b\u306e\u8cea\u3092\u8457\u3057\u304f\u4f4e\u4e0b\u3055\u305b\u308b\u3060\u3051\u3067\u306a\u304f\u3001\u793e\u4f1a\u7d4c\u6e08\u7684\u306a\u8ca0\u62c5\u3082\u5927\u304d\u3044\u3053\u3068\u304b\u3089\u3001\u52b9\u679c\u7684\u306a\u6cbb\u7642\u6cd5\u3078\u306e\u30cb\u30fc\u30ba\u306f\u7d76\u3048\u305a\u9ad8\u307e\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>*   **\u4e16\u754c\u7684\u306a\u9ad8\u9f62\u8005\u4eba\u53e3\u306e\u6025\u5897**:<br \/>\n    \u9ad8\u9f62\u8005\u4eba\u53e3\u306e\u5897\u52a0\u306f\u3001\u773c\u79d1\u75be\u60a3\u3001\u7279\u306bAMD\u306e\u75c7\u4f8b\u6570\u3092\u5897\u52a0\u3055\u305b\u308b\u4e3b\u8981\u306a\u4eba\u53e3\u7d71\u8a08\u5b66\u7684\u8981\u56e0\u3067\u3059\u3002\u56fd\u9023\u7d4c\u6e08\u793e\u4f1a\u5c40\u306e\u30c7\u30fc\u30bf\u306b\u3088\u308b\u3068\u3001\u4e16\u754c\u306e60\u6b73\u4ee5\u4e0a\u306e\u9ad8\u9f62\u8005\u4eba\u53e3\u306f2019\u5e74\u6642\u70b9\u3067\u7d047\u5104300\u4e07\u4eba\u306b\u9054\u3057\u3066\u304a\u308a\u30012016\u5e74\u306e6%\u304b\u30892019\u5e74\u306b\u306f9%\u3078\u3068\u300165\u6b73\u4ee5\u4e0a\u306e\u4eba\u53e3\u5272\u5408\u304c\u7740\u5b9f\u306b\u4e0a\u6607\u3057\u3066\u3044\u307e\u3059\u3002\u9ad8\u9f62\u5316\u306f\u3001AMD\u306e\u767a\u75c7\u30ea\u30b9\u30af\u3092\u98db\u8e8d\u7684\u306b\u9ad8\u3081\u308b\u3053\u3068\u304c\u77e5\u3089\u308c\u3066\u304a\u308a\u3001\u3053\u306e\u4eba\u53e3\u52d5\u614b\u306e\u5909\u5316\u306f\u3001Anti-VEGF\u6cbb\u7642\u85ac\u306e\u6f5c\u5728\u7684\u306a\u60a3\u8005\u57fa\u76e4\u3092\u5927\u5e45\u306b\u62e1\u5927\u3057\u3066\u3044\u307e\u3059\u3002\u7d50\u679c\u3068\u3057\u3066\u3001AMD\u306e\u8a3a\u65ad\u4ef6\u6570\u306e\u5897\u52a0\u304cAnti-VEGF\u6cbb\u7642\u85ac\u5e02\u5834\u306e\u6301\u7d9a\u7684\u306a\u6210\u9577\u3092\u5f37\u529b\u306b\u5f8c\u62bc\u3057\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>*   **\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u958b\u767a\u3078\u306e\u7a4d\u6975\u7684\u306a\u7814\u7a76\u958b\u767a\uff08R&#038;D\uff09\u6295\u8cc7**:<br \/>\n    \u591a\u304f\u306e\u88fd\u85ac\u4f01\u696d\u3084\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u304c\u3001\u9769\u65b0\u7684\u306aAnti-VEGF\u6cbb\u7642\u85ac\u306e\u958b\u767a\u306b\u591a\u5927\u306a\u7814\u7a76\u958b\u767a\u6295\u8cc7\u3092\u884c\u3063\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u306f\u3001\u524d\u8ff0\u306e\u75be\u60a3\u6709\u75c5\u7387\u306e\u6025\u901f\u306a\u5897\u52a0\u306b\u5bfe\u5fdc\u3059\u308b\u305f\u3081\u3001\u3088\u308a\u52b9\u679c\u7684\u3067\u3001\u3088\u308a\u5b89\u5168\u3067\u3001\u304b\u3064\u4f5c\u7528\u6301\u7d9a\u6642\u9593\u306e\u9577\u3044\u65b0\u3057\u3044\u6cbb\u7642\u6cd5\u3078\u306e\u9ad8\u3044\u30cb\u30fc\u30ba\u304c\u5b58\u5728\u3059\u308b\u305f\u3081\u3067\u3059\u3002\u73fe\u5728\u306eAnti-VEGF\u6cbb\u7642\u85ac\u306f\u975e\u5e38\u306b\u52b9\u679c\u7684\u3067\u3042\u308b\u3082\u306e\u306e\u3001\u591a\u304f\u306e\u5834\u5408\u3001\u983b\u7e41\u306a\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u304c\u5fc5\u8981\u3067\u3042\u308a\u3001\u3053\u308c\u304c\u60a3\u8005\u306e\u8ca0\u62c5\u3084\u6cbb\u7642\u30a2\u30c9\u30d2\u30a2\u30e9\u30f3\u30b9\u306e\u8ab2\u984c\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u305f\u3081\u3001\u4f5c\u7528\u6301\u7d9a\u671f\u9593\u3092\u5ef6\u9577\u3057\u3001\u6295\u4e0e\u983b\u5ea6\u3092\u6e1b\u3089\u3059\u3053\u3068\u3092\u76ee\u6307\u3057\u305f\u65b0\u898f\u85ac\u5264\u3084\u85ac\u7269\u9001\u9054\u30b7\u30b9\u30c6\u30e0\u306e\u958b\u767a\u306b\u91cd\u70b9\u304c\u7f6e\u304b\u308c\u3066\u3044\u307e\u3059\u3002\u88fd\u85ac\u4f01\u696d\u306f\u3001\u3088\u308a\u9ad8\u3044\u5e02\u5834\u30b7\u30a7\u30a2\u3092\u7372\u5f97\u3057\u3001\u60a3\u8005\u306e\u5b89\u5168\u3092\u78ba\u4fdd\u3057\u306a\u304c\u3089\u3001\u533b\u7642\u6a5f\u95a2\u3084\u5b66\u8853\u6a5f\u95a2\u3068\u7dca\u5bc6\u306b\u9023\u643a\u3057\u3066\u5927\u898f\u6a21\u306a\u81e8\u5e8a\u8a66\u9a13\u3092\u5b9f\u65bd\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u3088\u3046\u306a\u7d99\u7d9a\u7684\u306a\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3078\u306e\u53d6\u308a\u7d44\u307f\u304c\u3001\u5e02\u5834\u306e\u6210\u9577\u3092\u3055\u3089\u306b\u52a0\u901f\u3055\u305b\u308b\u539f\u52d5\u529b\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>**3. \u5e02\u5834\u306e\u963b\u5bb3\u8981\u56e0**<\/p>\n<p>Anti-VEGF\u6cbb\u7642\u85ac\u5e02\u5834\u306f\u529b\u5f37\u3044\u6210\u9577\u3092\u898b\u305b\u308b\u4e00\u65b9\u3067\u3001\u305d\u306e\u62e1\u5927\u3092\u59a8\u3052\u308b\u53ef\u80fd\u6027\u306e\u3042\u308b\u3044\u304f\u3064\u304b\u306e\u91cd\u8981\u306a\u8ab2\u984c\u306b\u3082\u76f4\u9762\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>*   **\u4e3b\u8981\u88fd\u54c1\u306e\u30d1\u30c6\u30f3\u30c8\u30af\u30ea\u30d5\u3068\u30d0\u30a4\u30aa\u30b7\u30df\u30e9\u30fc\u306e\u53f0\u982d**:<br \/>\n    \u88fd\u85ac\u696d\u754c\u306b\u304a\u3051\u308b\u6700\u3082\u6df1\u523b\u306a\u8ab2\u984c\u306e\u4e00\u3064\u304c\u300c\u30d1\u30c6\u30f3\u30c8\u30af\u30ea\u30d5\u300d\u3001\u3059\u306a\u308f\u3061\u30d6\u30ed\u30c3\u30af\u30d0\u30b9\u30bf\u30fc\u85ac\u306e\u7279\u8a31\u5207\u308c\u3067\u3059\u3002\u3053\u308c\u3089\u306e\u85ac\u5264\u306f\u901a\u5e38\u3001\u4f01\u696d\u306e\u7dcf\u53ce\u76ca\u306e\u5927\u90e8\u5206\u3092\u5360\u3081\u3066\u3044\u308b\u305f\u3081\u3001\u7279\u8a31\u4fdd\u8b77\u306e\u55aa\u5931\u306f\u4f01\u696d\u306e\u8ca1\u52d9\u72b6\u6cc1\u306b\u5927\u304d\u306a\u6253\u6483\u3092\u4e0e\u3048\u307e\u3059\u3002\u8fd1\u5e74\u3001F. Hoffmann-La Roche Ltd.\u306e\u300c\u30eb\u30bb\u30f3\u30c6\u30a3\u30b9\uff08Lucentis\uff09\u300d\u306f\u7c73\u56fd\u30672020\u5e746\u6708\u306b\u3001\u307e\u305f\u7db2\u819c\u9759\u8108\u9589\u585e\u75c7\uff08RVO\uff09\u3084\u52a0\u9f62\u9ec4\u6591\u5909\u6027\u75c7\uff08AMD\uff09<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.marketresearch.co.jp\/insights\/wp-json\/wp\/v2\/posts\/63017"}],"collection":[{"href":"https:\/\/www.marketresearch.co.jp\/insights\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketresearch.co.jp\/insights\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketresearch.co.jp\/insights\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketresearch.co.jp\/insights\/wp-json\/wp\/v2\/comments?post=63017"}],"version-history":[{"count":0,"href":"https:\/\/www.marketresearch.co.jp\/insights\/wp-json\/wp\/v2\/posts\/63017\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketresearch.co.jp\/insights\/wp-json\/wp\/v2\/media?parent=63017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketresearch.co.jp\/insights\/wp-json\/wp\/v2\/categories?post=63017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketresearch.co.jp\/insights\/wp-json\/wp\/v2\/tags?post=63017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}